Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes.

Abstract:

BACKGROUND/AIMS:The role of antibody in hepatitis C virus (HCV) infection remains unclear although many reports attest to its role in viral clearance. Here we describe epitopes that are recognized by antibody present in the serum of infected patients and show that such epitopes can induce neutralizing antibodies. METHODS:Human serum containing hyperimmune anti-HCV IgG was used to extract epitopes from a library of synthetic peptides that encompassed the sequences of the E1 and E2 proteins of HCV genotype 1a H77. Peptides that were bound by IgG were identified by mass spectrometry. Assembly of these epitopes with a helper T cell determinant was then carried out in order to construct candidate epitope-based vaccines. RESULTS:Three distinct antigenic sites were defined in the E1E2 glycoproteins by epitopes identified by antibody present in infected individuals. Four of the peptide epitopes identified are conserved in at least three HCV genotypes and are bound by antibody present in the sera of chronically infected and convalescent individuals. Synthetic vaccines based on these epitopes elicited antibodies that are capable of (i) capturing HCV virions from the serum of viraemic patients and (ii) inhibiting HCV pseudovirus particle entry into Huh7 cells. CONCLUSIONS:This approach exploits the information inherent in the binding sites of virus-specific antibodies and represents a novel method for the design of synthetic epitope-based vaccines.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Grollo L,Torresi J,Drummer H,Zeng W,Williamson N,Jackson DC

subject

Has Abstract

pub_date

2006-01-01 00:00:00

pages

1005-14

issue

8

eissn

1359-6535

issn

2040-2058

journal_volume

11

pub_type

杂志文章
  • The hepatitis C virus NS3 proteinase: structure and function of a zinc-containing serine proteinase.

    abstract::The hepatitis C virus (HCV) NS3 protein contains a serine proteinase domain implicated in the maturation of the viral polyprotein. NS3 forms a stable heterodimer with NS4A, a viral membrane protein that acts as an activator of the NS3 proteinase. The three-dimensional structure of the NS3 proteinase complexed with an ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: De Francesco R,Pessi A,Steinkühler C

    更新日期:1998-01-01 00:00:00

  • Treatment of hepatitis C in two paediatric patients using sofosbuvir during haematopoietic stem cell transplantation.

    abstract::We report the first two paediatric cases of sofosbuvir treatment during high-intensity myeloablative conditioning and engraftment phases of haematopoietic stem cell transplantation. These reports highlight the safety of sofosbuvir during all phases of transplantation and the lack of interaction between sofosbuvir and ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3332

    authors: Grasso AG,Sonzogni A,Zanon D,Maestro A,Loiacono S,Maximova N

    更新日期:2019-01-01 00:00:00

  • A randomized pahse I bioequivalence clinincal trial of a paediatric fixed-dose combination antiretroviral reconstitutable suspension in healthy adult volunteers.

    abstract:BACKGROUND:This study aimed to test the hypothesis that the paediatric fixed-dose combination granule for reconstitution (comprising lamivudine/zidovudine/nevirapine 30/60/50 mg per 5 ml) as a test product is bioequivalent to the coadministered single entities of the referenced products. Fixed-dose combination anti-ret...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,随机对照试验,评审

    doi:10.3851/imp2310

    authors: Esseku F,Joshi A,Oyegbile Y,Edowhorhu G,Gbadero D,Adeyeye M

    更新日期:2013-01-01 00:00:00

  • The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells.

    abstract:OBJECTIVES:Clinical disorders occurring in HIV-infected patients on antiretroviral therapy (ART) have been linked to mitochondrial dysfunction, for example, lactic acidosis and lipodystrophy. Mitochondrial membrane potential (delta psi m) is the most direct measure of the state of energization of the mitochondria. We a...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Sternfeld T,Schmid M,Tischleder A,Mudra S,Schlamp A,Kost BP,Gruber R,Youle M,Bogner JR,Goebel FD

    更新日期:2007-01-01 00:00:00

  • Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy.

    abstract::We assessed the prevalence and clinical impact of insertions within the HIV-1 p6Gag proline-rich (PTAP) region on initial antiretroviral therapy response in 461 HIV-infected, drug-naive individuals initiating therapy in British Columbia, Canada between June 1996 and August 1998. HIV p6Gag insertions were detected by n...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Brumme ZL,Chan KJ,Dong WW,Wynhoven B,Mo T,Hogg RS,Montaner JS,O'Shaughnessy MV,Harrigan PR

    更新日期:2003-04-01 00:00:00

  • Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.

    abstract:OBJECTIVE:To assess the baseline factors associated with haematological toxicity that lead to ribavirin or pegylated interferon (peginterferon) dosage reductions in hepatitis C and human immunodeficiency virus (HCV/HIV)-coinfected patients. DESIGN:Multicentre, prospective, observational study. SETTING:Eleven hospital...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Fuster D,Huertas JA,Gómez G,Solà R,González García J,Vilaró J,Pedrol E,Force L,Tor J,Sirera G,Videla S,Planas R,Clotet B,Tural C,PEG-TOX Research Group.

    更新日期:2005-01-01 00:00:00

  • In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis.

    abstract:BACKGROUND:In vitro studies have reported controversial effects of protease inhibitors (PIs) on mitochondrially driven apoptosis. Additionally, since PIs in the clinical setting are almost always given in combination with nucleoside analogues, which may have negative effects on mitochondrial DNA (mtDNA), the impact of ...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Miró O,Villarroya J,Garrabou G,López S,Rodríguez de la Concepción M,Pedrol E,Martínez E,Giralt M,Gatell JM,Cardellach F,Casademont J,Villarroya F

    更新日期:2005-01-01 00:00:00

  • Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.

    abstract:BACKGROUND:This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment. METHODS:A total of 243 patients from Cameroon receiving d4T or zidovudine (AZT) in combination with lamivudine and efavirenz or nevirapine for >6 months were clinically assesse...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1664

    authors: Cournil A,Coudray M,Kouanfack C,Essomba CN,Tonfack CA,Biwolé-Sida M,Delaporte E,Bork K,Laurent C

    更新日期:2010-01-01 00:00:00

  • HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B.

    abstract::Although chronic HBV infection is the leading cause of chronic liver disease and death worldwide, there are substantial differences in its clinical courses regarding prevalence, mode of transmission, characteristics of each phase, responses to antiviral therapy, and development of cirrhosis and hepatocellular carcinom...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP1982

    authors: Kim BK,Revill PA,Ahn SH

    更新日期:2011-01-01 00:00:00

  • K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.

    abstract::Antiretroviral treatment with three nucleoside reverse transcriptase inhibitors (NRTIs) is widely used, but the combination of abacavir, didanosine and stavudine has never been investigated. We describe the surprising and consistent genotypic and phenotypic outcome in patients failing this combination. As part of a Da...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Røge BT,Katzenstein TL,Obel N,Nielsen H,Kirk O,Pedersen C,Mathiesen L,Lundgren J,Gerstoft J

    更新日期:2003-04-01 00:00:00

  • Sodium tanshinone IIA sulfonate inhibits porcine reproductive and respiratory syndrome virus via suppressing N gene expression and blocking virus-induced apoptosis.

    abstract:BACKGROUND:Porcine reproductive and respiratory syndrome virus (PRRSV) causes significant economic loss in the swine industry. Currently, there is no effective way to prevent PRRSV infection. Sodium tanshinone IIA sulfonate (STS), a natural compound derived from Salvia miltiorrhiza, was shown to possess anti-PRRSV acti...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2694

    authors: Sun N,Li E,Wang Z,Zhao J,Wang S,He J,Bai Y,Li H

    更新日期:2014-01-01 00:00:00

  • Biphasic pattern of depression and its predictors during pegylated interferon-based therapy in chronic hepatitis B and C patients.

    abstract:BACKGROUND:It remains unclear whether depression in chronic hepatitis B (CHB) and chronic hepatitis C (CHC) during pegylated interferon-based therapy is associated with the virus, drug or ethnic background. We aimed to perform a prospective study to evaluate the clinical course of depression and its predictors in conse...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2441

    authors: Huang YW,Hu JT,Hu FC,Chang CJ,Chang HY,Kao JH,Yang SS,Chen DS

    更新日期:2013-01-01 00:00:00

  • Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.

    abstract:OBJECTIVES:To assess potential pharmacokinetic (PK) interactions between atazanavir (ATV, 300 mg, once daily) and lopinavir (LPV, 400 mg, twice daily), both boosted by ritonavir (RTV, 100 mg). DESIGN:Two-parallel groups, addition of LPV in patients receiving ATV (n=6), and addition of ATV in patients receiving LPV (n=...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Colombo S,Buclin T,Franc C,Guignard N,Khonkarly M,Tarr PE,Rochat B,Biollaz J,Telenti A,Decosterd LA,Cavassini M

    更新日期:2006-01-01 00:00:00

  • The protease inhibitors ritonavir and saquinavir influence lipid metabolism: a pig model for the rapid evaluation of new drugs.

    abstract:BACKGROUND:Studies of the effects of antiretroviral drugs on lipid metabolism are limited by the availability of suitable models. We have thus developed an animal model utilising Göttingen mini-pigs. The normal lipid metabolism of mini-pigs closely reflects that of humans and they are expected to have similar reactions...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1509

    authors: Petersen E,Mu H,Porsgaard T,Bertelsen LS

    更新日期:2010-01-01 00:00:00

  • Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.

    abstract:BACKGROUND:A significant proportion of hepatitis C patients treated with unmodified interferon plus ribavirin fail to respond. The optimal therapy for these patients has not been established yet. The objective of this study was to assess the efficacy and safety of peginterferon plus ribavirin with or without amantidine...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Hasan F,Al-Khaldi J,Asker H,Al-Ajmi M,Owayed S,Varghese R,Siddique I,Al-Nakib B

    更新日期:2004-08-01 00:00:00

  • Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice.

    abstract:BACKGROUND:Virological success (VS) and immunological reconstitution (IR) of antiretroviral-naive HIV-1-infected patients with pre-therapy viral load (VL) >500,000 copies/ml was assessed after 12 months of treatment according to initial drug-class regimens. METHODS:An observational multicentre retrospective study was ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3197

    authors: Santoro MM,Di Carlo D,Armenia D,Zaccarelli M,Pinnetti C,Colafigli M,Prati F,Boschi A,Antoni AMD,Lagi F,Sighinolfi L,Gervasoni C,Andreoni M,Antinori A,Mussini C,Perno CF,Borghi V,Sterrantino G

    更新日期:2018-01-01 00:00:00

  • External quality assessment of HLA-B*5701 reporting: an international multicentre survey.

    abstract:OBJECTIVES:HLA-B*5701 strongly predicts abacavir hypersensitivity (HSR), but implementation of effective routine screening into clinical practice requires testing be practical and accurate. We tested the proficiency of HLA-B*5701 typing among laboratories using sequence-specific primer PCR. DESIGN AND METHODS:DNA pane...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:

    authors: Hammond E,Almeida CA,Mamotte C,Nolan D,Phillips E,Schollaardt TA,Gill MJ,Angel JB,Neurath D,Li J,Giulivi T,McIntyre C,Koultchitski G,Wong B,Reis M,Rachlis A,Cole DE,Chew CB,Neifer S,Lalonde R,Roger M,Jeanneau A

    更新日期:2007-01-01 00:00:00

  • Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-

    abstract:BACKGROUND:Once-daily dosing of abacavir and lamivudine has been approved for adults, but paediatric data are insufficient. We conducted a pharmacokinetic study of once-daily and twice-daily abacavir and lamivudine in children aged 3-<36 months. METHODS:Children with stable HIV type-1 (HIV-1) RNA levels after 12 weeks...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3851/IMP1532

    authors: Paediatric European Network for Treatment of AIDS (PENTA).

    更新日期:2010-01-01 00:00:00

  • Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.

    abstract:OBJECTIVE:The aim of the study was to analyse the response to highly active antiretroviral therapy (HAART) initiated at the time of primary HIV infection (PHI) in patients infected with a virus resistant to > or = 1 drug of their treatment compared with patients infected with a wild-type virus. METHODS:We analysed dat...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Chaix ML,Desquilbet L,Descamps D,Costagliola D,Deveau C,Galimand J,Goujard C,Signori-Schmuck A,Schneider V,Tamalet C,Pellegrin I,Wirden M,Masquelier B,Brun-Vezinet F,Rouzioux C,Meyer L,French PRIMO Cohort Study Group (ANR

    更新日期:2007-01-01 00:00:00

  • Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay.

    abstract:BACKGROUND:Patients infected with hepatitis C virus (HCV) who respond to treatment with interferon-alpha plus ribavirin exhibit biphasic or triphasic viral load decreases. While the rapid first phase is indicative of the effectiveness of therapy in blocking viral production (epsilon), the slope of the final phase (lamb...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Dahari H,Shudo E,Cotler SJ,Layden TJ,Perelson AS

    更新日期:2009-01-01 00:00:00

  • Therapeutic drug monitoring of antiretroviral drugs at home using dried blood spots: a proof-of-concept study.

    abstract:BACKGROUND:In HIV-infected patients, therapeutic drug monitoring (TDM) of antiretroviral drugs is recommended in special populations and in specific situations to optimize therapy. Currently, TDM is performed via measurement of drug plasma concentrations; however, dried blood spots (DBS) may offer a patient friendly an...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2501

    authors: Kromdijk W,Mulder JW,Smit PM,Ter Heine R,Beijnen JH,Huitema AD

    更新日期:2013-01-01 00:00:00

  • HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents.

    abstract::Chronic hepatitis C affects approximately 170 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. Until 2011, the only therapeutic option was combination therapy of pegylated interferon and ribavirin, with efficacy rates around 50% and plenty of side effects. In the past...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2425

    authors: Calle Serrano B,Manns MP

    更新日期:2012-01-01 00:00:00

  • ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection.

    abstract:BACKGROUND:ITX 5061 is a highly potent small molecule inhibitor of scavenger receptor-B1, an integral transmembrane protein that is found in liver cells and is actively involved in the transport of HCV into hepatocytes. Currently, ITX 5061 is being investigated in monoinfected hepatitis C patients in a proof-of-concept...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2354

    authors: Hochreiter J,Lapham J,Wong-Staal F,McKelvy J,Sulkowski M,Glesby MJ,Johnson VA,Morse GD

    更新日期:2013-01-01 00:00:00

  • P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir.

    abstract:BACKGROUND:Drug efflux (for example, P-glycoprotein [P-gp], multidrug resistance-associated proteins [MRPs] and breast cancer resistance protein [BCRP]) and influx (for example, human organic anion transporting polypeptide [hOCTP] or human organic anion transporting polypeptide [hOATP]) transporters alter the cellular ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1399

    authors: Janneh O,Anwar T,Jungbauer C,Kopp S,Khoo SH,Back DJ,Chiba P

    更新日期:2009-01-01 00:00:00

  • Hepatitis C virus kinetics.

    abstract::The balance of virus production and clearance for untreated patients with chronic hepatitis C virus (HCV) results in a decline of viraemia when initiating active antiviral treatment. During the first phase of interferon-alpha therapy, after a delay of about 8-9 h, the kinetics of the viral load is characterized by a r...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Herrmann E,Neumann AU,Schmidt JM,Zeuzem S

    更新日期:2000-06-01 00:00:00

  • Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?

    abstract:BACKGROUND:Increasing efavirenz (EFV) dose from 600 mg to 800 mg daily has been suggested with concomitant rifampicin (RFN), as induction of cytochrome P450 isoenzymes may reduce EFV plasma concentrations. METHODS:Individuals from the CIPRA-South Africa cohort taking EFV-based antiretroviral therapy with concomitant t...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:10.3851/IMP1780

    authors: Orrell C,Cohen K,Conradie F,Zeinecker J,Ive P,Sanne I,Wood R

    更新日期:2011-01-01 00:00:00

  • Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4

    abstract:OBJECTIVE:To assess the effect of interleukin (IL)-2 combined with highly active antiretroviral therapy (HAART) on HIV-1 pro-viral DNA quantification in HIV-1-infected patients with CD4<200/mm3. PATIENTS AND METHODS:Seventy patients with CD4<200 cells/mm3 and CV<1000 copies/ml were enrolled in a 6-month randomized con...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Delaugerre C,Gourlain K,Tubiana R,Carcelain G,Marcelin AG,Chouquet C,Mouroux M,Duvivier C,Autran B,Costagliola D,Katlama C,Calvez V

    更新日期:2003-06-01 00:00:00

  • Do we need genotypic weighted resistance scores for antiretrovirals? The curious case of tipranavir.

    abstract::Weighted genotypic resistance scores represent a step towards excellence in the interpretation of HIV type-1 (HIV-1) resistance to antiretroviral drugs. They can predict phenotypic resistance and clinical response better than any other unweighted score. With the addition of mutations associated with an increased respo...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1671

    authors: Llibre JM

    更新日期:2010-01-01 00:00:00

  • Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.

    abstract:INTRODUCTION:Patients with hepatitis C recurrence after liver transplantation represent a clinical challenge. Antiviral treatment in transplant patients has usually poor tolerability and limited efficacy, with a mean sustained virological response (SVR) of 30%. Our pilot study was aimed at evaluating whether 8-week rib...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1834

    authors: Merli M,Giannelli V,Gentili F,Giusto M,Simmaco M,Lionetto L,Corradini SG,Biliotti E,Attili AF,Rossi M,Taliani G

    更新日期:2011-01-01 00:00:00

  • Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes.

    abstract:BACKGROUND:We examined whether waist circumference (WC) and self-reported abdominal size changes can estimate visceral adipose tissue (VAT) changes for those initiating antiretroviral therapy (ART). METHODS:Prospectively collected data from ACTG A5257 and its metabolic substudy, A5260s, were used for this analysis. AR...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3148

    authors: Bhagwat P,Ofotokun I,McComsey GA,Brown TT,Moser C,Sugar CA,Currier JS

    更新日期:2017-01-01 00:00:00